Qi Qian

Ms. Qi Qian


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
QQQi Qian
Qi Qian
GFGuohao Fan
Guohao Fan
YWyang wei
yang wei
CSChenguang Shen
Chenguang Shen
YYYang Yang
Yang Yang
JYJianhai Yu
Jianhai Yu
Influenza poses a significant global health burden due to its high transmissibility, antigenic variability, and substantial morbidity. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has further complicated influenza dynamics, highlighting the need for rapid, accurate, and accessible diagnostics. This review comprehensively summarized the advancements in influenza virus (IFV) detection, from conventional methods like viral culture and serology to modern molecular techniques, including CRISPR-based systems, next-generation sequencing (NGS), and biosensors. We analyze the sensitivity, specificity, and applicability of these methods and emphasize their roles in clinical and public health settings. While traditional techniques remain valuable for strain characterization, novel technologies like CRISPR and portable biosensors offer rapid, low-resource solutions. This review provides a comprehensive insight into the development of integrated diagnostic strategies for seasonal IFV epidemics and future pandemics.

28 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
JWJiayang Wang
Jiayang Wang
QQQi Qian
Qi Qian
YJYushan Jiang
Yushan Jiang
ZLZuxin Liang
Zuxin Liang
YPYun Peng
Yun Peng
CSChenguang Shen
Chenguang Shen
Background/Objectives: COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic since its outbreak in 2019. As an increasing number of variants have emerged, especially concerning variants such as Omicron BA.1, BA.2, XBB.1, EG.5, which can escape the immune system and cause repeated infections, they have exerted significant pressure on monoclonal antibodies and the treatment approaches for COVID-19. Broad spectrum antiviral medication was urgently needed. In this study, we developed several bispecific antibodies based on the IgG-scFv format and one trispecific antibody containing Fab fragments with different anti-virus mechanisms studied previously. The Fab fragments are from h11B11, S2P6, and S309 respectively. Method: all recombinant antibodies were expressed by HEK 293. The pseudoviruses’ neutralization assay and the virus challenge to BALB/c mice were deployed to assess the efficiency of recombinant antibodies in vitro and in vivo. Results: the bispecific antibodies exhibited a favorable pseudoviruses neutralization activity, with IC50 values ranging from 8 to 591 ng/mL. The trispecific antibody performed even better, with IC50 values ranging from 5 to 27 ng/mL. Furthermore, the virus challenge to mice confirmed that the bispecific antibodies, including the trispecific antibody, had decent therapeutic efficacy. Conclusions: our study provided several supplements to the therapeutic measures of COVID-19 based on multispecific antibodies, supporting the great potential of the multispecific antibodies strategy in dealing with emerging pathogens.